Thomas Porstmann

Global Scientific Director
Novo Nordisk Health Care AG, Zurich, Switzerland

Presentation(s):

• OC 30.3 - Treatment Experience in Hemophilia Patients With and Without Inhibitors on Concizumab Prophylaxis: Hemo-TEM results from the phase 2 explorer4 & 5 studies

  Monday, July 11, 2022
  11:15 AM – 11:30 AM